Erik Gentalen Email and Phone Number
Greater Boston
Erik Gentalen's Location
Greater Boston, United States, United States
Erik Gentalen's Contact Details
Erik Gentalen work email
- Valid
- Valid
- Valid
- Valid
- Valid
- Valid
- Valid
Erik Gentalen personal email
n/a
About Erik Gentalen
I enjoy building companies from the ground up and leading a talented team in the development of new products to advance human health.Hands-on technology executive and entrepreneur. Have spent my career developing revolutionary products at early-stage startup companies - Intabio, ProteinSimple, Caliper and Affymetrix.*Product and corporate development, R&D and engineering leadership and intellectual property.*Intellectual Property strategy and portfolio / prosecution management; registered patent agent. *Technical expertise in biotherapeutics, drug development, analytical chemistry, biology, chemistry, microfluidics, capillary electrophoresis, protein characterization, microarrays, immunoassays, engineering. Publication summary: 10 peer-reviewed papers, 32 issued patents, 1 book chapter
Erik Gentalen's Current Company Details
Genoa Ventures
View
CEO, Co-Founder Upstart Science
Greater Boston
- Website:
- genoavc.com
- Employees:
- 15
Erik Gentalen Work Experience Details
-
Genoa VenturesGreater Boston
-
Co-Founder, CeoUpstart Science 2024 - PresentAt Upstart Science, we are focused on revolutionizing the design and manufacture of biologic medicines. Our innovative solutions to fundamental issues with current biologics will pave the way for a revolution in antimicrobial and therapeutic development. We aim to accelerate the development of life-saving treatments and ensure they are accessible to those in need, thus making a significant impact on global health outcomes. -
Entrepreneur In ResidenceGenoa Ventures Jun 2023 - PresentSan Francisco, Ca, UsGenoa Ventures (formerly 5 Prime Ventures) invests in early-stage companies innovating at the intersection of biology and technology, with a focus on opportunities in research tools, molecular diagnostics, synthetic biology, ag biotech, and industrial biology.
-
AdvisorSciex Oct 2021 - Sep 2023Framingham, Ma, UsAfter stepping down as GM, I have continued to advise the team on technical development of the Intabio ZT system, and integration of Intabio into SCIEX through the product launch in 2023. -
General Manager/Vp Intabio, LlcSciex Dec 2020 - Sep 2021Framingham, Ma, UsAfter the acquisition of Intabio by SCIEX in December 2020, I assumed the role of General Manager of the Intabio site. I oversaw all aspects of development of the Intabio ZT system and worked with the SCIEX team to ensure a smooth transition. This involved working closely with cross-functional teams to align our development efforts and leverage the resources and expertise available within the SCIEX organization, as well as maintaining a strong focus on the ongoing development of the Intabio ZT system.
-
Founder, Chief Technology Officer, Vp Intellectual PropertyIntabio (Acquired By Sciex In Dec 2020) Oct 2015 - Dec 2020I founded Intabio in 2015 to address the challenges faced by the biopharmaceutical industry in producing complex biologic drug therapies. Although these therapies have spurred on extraordinary advances in medicine, they are notoriously difficult to develop and manufacture. Much of this stems from the fact that current analytical systems are cumbersome and provide neither the throughput nor bandwidth that the biopharma industry desperately needs. This leads to incomplete knowledge of the product quality, and costly missteps and delays during development.At Intabio, we developed a microfluidic platform that provides real-time direct characterization of intact protein variants, enabling true simultaneous multiple-attribute-monitoring (MAM). This reduces analytical cycle time from weeks to minutes and allows multiple critical quality attributes to be rapidly characterized in one unified assay.In 3 ½ years, we successfully raised $38M and established successful collaborations with a dozen leading biopharma companies, including Pfizer, Genentech, Boehringer-Ingelheim, Janssen, AstraZeneca, and Bayer. We had active development relationships with three instrument companies, and were supporting two beta units at customer sites when we were acquired by SCIEX in 2020. - As founding employee, established technical, IP and marketing validation to secure funding and hire R&D and business teams. - Invented, wrote and filed initial patent applications. inventor on 23 issued patents covering Intabio's technologies. Managed company portfolio and prosecution with outside counsel- Managed R&D efforts, development of platform (instrument, consumables, software), collaboration and customer relationships- PI on $2.3M NIH-SBIR Phase I/II Fast Track ,$225K NSF-SBIR Phase I, and $175K NIIMBL grant with Merck, Genentech, Celgene, and Millipore-Sigma.- Raised $38M from June 2017-December 2019 (including $2.7M in grants). Acquired by SCIEX in Dec 2020
-
Board MemberIntabio Oct 2015 - Dec 2020
-
CeoIntabio Oct 2015 - Apr 2017
-
Director, Systems Integration / Product SupportProteinsimple 2003 - 2015San Jose, Ca, UsProteinsimple provides protein analysis tools to biological research and pharma for biologic drug characterization, immunoassay, aggregation (particle sizing), and gel imaging.As the fourth employee at ProteinSimple, I led the R&D team that developed the Simple Western capillary electrophoresis based immunoassay platform from invention through launch and managed early access collaborations with National Cancer Institute, Sloane Kettering, Lawrence Berkeley National Labs and Merck. The Simple Western instruments are now used at hundreds of laboratories within leading research institutions, CROs and pharma as a more sensitive and more quantitative alternative to western blotting.As ProteinSimple grew, I worked on technical support and development of acquired technologies, including the iCE capillary-based imaged IEF platform, which became the gold standard for charge heterogeneity analysis of biologic drugs. Additionally, I developed training classes for field scientists and engineers and quality programs (IQ/OQ/PQ/PM) for all product lines. In addition to my technical role, I also managed ProteinSimple’s intellectual property portfolio where I was instrumental in working with the USPTO to facilitate the issuance of ProteinSimple’s first four patents, performed FTO analysis for each new product, managed prosecution of patent applications, and assisted in litigation. ProteinSimple was acquired by Bio-Techne in 2014 for $300M -
Program Manager / Senior ScientistCaliper Technologies 2000 - 2003Caliper Life Sciences was a pioneer in microfluidics and the first company to commercialize microfluidic chip technology. I joined in 2000 as a Program Manager and Senior Scientist, where I led system integration of a microfluidic "application developer" system from concept to launch, developed chip designs for customer applications, and managed application development collaborations with pharmaceutical and industrial partners, including Glaxo-SmithKline, Millennium Pharmaceuticals (now Takeda) and Ambion. In addition to instrument development, my role was to provide microfluidic expertise and to develop microchips based on collaborator input. These collaborations focused on creating microfluidic solutions for challenges in areas such as chemical analysis, high throughput drug screening, protein quantitation and on-chip single cell gene expression analysis. The use of microfluidics enabled the collaborating companies to develop analytical systems that could work with much smaller samples sizes, reduced hands-on time, and minimized the user expertise required to run the assays. Caliper was acquired by Perkin-Elmer in 2010 for $600M -
Manager, Systems OptimizationCombimatrix 1999 - 2000At Combimatrix, we developed CMOS silicon chips for electrochemical synthesis and detection of peptides and DNA. I joined in 1999 as the 13th employee, where I led design of first multi-array DNA synthesizer, wrote instrument software, and transferred synthesis processes from prototype to scale-up. I managed process development team for electrochemical peptide and DNA array synthesis and developed analytical methods for synthesis characterization.The array technology was later spun out of Combimatrix as Custom Array Inc., which provides DNA array synthesizers for rapid in-situ array synthesis for gene expression, and custom oligo pools for synthetic biology applications.
-
Staff EngineerAffymetrix 1992 - 1999Santa Clara, California, UsAffymetrix was the world leader in DNA array development, and the first company to commercialize DNA arrays. The photolithographic DNA synthesis method we developed allowed DNA probes to be manufactured at densities up to 1,000,000 probe sequences per square centimeter.I joined Affymetrix as its 15th employee in 1992. At the time gene expression analysis was typically done by Northern blot for one or only a handful of genes at a time. The development of arrays at Affymetrix allowed the simultaneous analysis of as many as 10,000 transcripts by the time I left in 1999. Since then, the array technology we developed has spawned multiple diagnostics products in collaboration with Roche. My contributions to the technology included development of its chemical synthesis technique, prototype instrument development, manufacture of the first 1000 custom arrays (p53, HIV, mitochondrial genome sequencing), in addition to managing process development and chemistry in the scale up process to manufacturing platform. As the technology matured, my role shifted to running a research-scale chip fabrication facility, developing novel arrays in collaboration with internal researchers and external scientists at Ron Davis’ and George Church’s as well as for my own research. In addition, I was responsible for process changes generating yield improvements and technology transfer from my fab to the commercial manufacturing floor. The Affymetrix array technology has enabled over 30,000 research publications and countless discoveries regarding gene expression in human health. 5 issued patents, 5 publicationsAffymetrix was acquired by Thermo-Fisher in 2016 for $1.6B
Erik Gentalen Skills
Assay Development
Molecular Biology
Biotechnology
Intellectual Property
Biochemistry
Commercialization
Technology Transfer
Start Ups
Dna
Protein Chemistry
R&d
Genomics
Biopharmaceuticals
Integration
Medical Devices
Validation
Python
R
Autodesk Inventor
Cross Functional Team Leadership
Capillary Electrophoresis
Laboratory Automation
Sbir
Erik Gentalen Education Details
-
Massachusetts Institute Of TechnologyBiology
Frequently Asked Questions about Erik Gentalen
What company does Erik Gentalen work for?
Erik Gentalen works for Genoa Ventures
What is Erik Gentalen's role at the current company?
Erik Gentalen's current role is CEO, Co-Founder Upstart Science.
What is Erik Gentalen's email address?
Erik Gentalen's email address is er****@****bio.com
What schools did Erik Gentalen attend?
Erik Gentalen attended Massachusetts Institute Of Technology.
What skills is Erik Gentalen known for?
Erik Gentalen has skills like Assay Development, Molecular Biology, Biotechnology, Intellectual Property, Biochemistry, Commercialization, Technology Transfer, Start Ups, Dna, Protein Chemistry, R&d, Genomics.
Who are Erik Gentalen's colleagues?
Erik Gentalen's colleagues are Vatshal Bhanushali.
Free Chrome Extension
Find emails, phones & company data instantly
Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Aero Online
Your AI prospecting assistant
Select data to include:
Total price:
$0.00
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial